A NEW ERA OF FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITION IN CHOLANGIOCARCINOMA

被引：2
|
作者：
Lamarca, A. [1 ,2 ]
Moreno, V. [3 ]
Gambardella, V. [4 ,5 ]
Cervantes, A. [4 ,5 ]
机构：
[1] Fdn Jimenez Diaz Univ Hosp, Oncohealth Inst, Dept Med Oncol, Madrid, Spain
[2] Christie NHS Fdn Trust, Dept Med Oncol, Manchester, England
[3] Fdn Jimenez Diaz Univ Hosp, Dept Med Oncol, START FJD Phase Unit 1, Madrid, Spain
[4] Univ Valencia, Hosp Clin Univ, INCLIVA Biomed Res Inst, Valencia, Spain
[5] Inst Salud Carlos III, CIBERONC, Madrid, Spain
来源：
ESMO OPEN | 2023年 / 8卷 / 06期
关键词：
METASTATIC CHOLANGIOCARCINOMA; OPEN-LABEL; MULTICENTER; EFFICACY;
D O I：
10.1016/j.esmoop.2023.102032
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Inhibition of fibroblasts reduced head and neck cancer growth by targeting fibroblast growth factor receptor
    Sweeny, Larissa
    Liu, Zhiyong
    Lancaster, William
    Hart, Justin
    Hartman, Yolanda E.
    Rosenthal, Eben L.
    LARYNGOSCOPE, 2012, 122 (07): : 1539 - 1544
  • [32] Clinical response to futibatinib in intrahepatic cholangiocarcinoma with acquired resistance to fibroblast growth factor receptor 2 inhibitors
    Casalino, S.
    Gerdes, C.
    Saborowski, A.
    Quinzii, A.
    Zecchetto, C.
    Sordo, A.
    Messineo, L.
    Leta, L. C.
    Lucin, E.
    Mendo, L.
    Pietrobono, S.
    Vogel, A.
    Melisi, D.
    ANNALS OF ONCOLOGY, 2024, 35 : S128 - S129
  • [33] Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma
    Tsujie, Masanori
    Iwai, Tomohisa
    Kubo, Shoji
    Ura, Takashi
    Hatano, Etsuro
    Sakai, Daisuke
    Takeda, Yutaka
    Kaibori, Masaki
    Kobayashi, Tomoe
    Katanuma, Akio
    Katayose, Yu
    Fukase, Koji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (06) : 911 - 917
  • [34] Fibroblast Growth Factor Receptor 2 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Cholangiocarcinoma
    Arai, Yasuhito
    Totoki, Yasushi
    Hosoda, Fumie
    Shirota, Tomoki
    Hama, Natsuko
    Nakamura, Hiromi
    Ojima, Hidenori
    Furuta, Koh
    Shimada, Kazuaki
    Okusaka, Takuji
    Kosuge, Tomoo
    Shibata, Tatsuhiro
    HEPATOLOGY, 2014, 59 (04) : 1427 - 1434
  • [35] Fibroblast growth factor receptor 4 promotes progression and correlates Cross Mark to poor prognosis in cholangiocarcinoma
    Xu, Yun-Fei
    Yang, Xiao-Qing
    Lu, Xiao-Fei
    Guo, Sen
    Liu, Yi
    Iqbal, Mohammad
    Ning, Shang-Lei
    Yang, Hui
    Suo, Ning
    Chen, Yu-Xin
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2014, 446 (01) : 54 - 60
  • [36] Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations
    Lee, Patrick C.
    Hendifar, Andrew
    Osipov, Arsen
    Cho, May
    Li, Daneng
    Gong, Jun
    CANCERS, 2021, 13 (07)
  • [37] A Case of Fibroblast Growth Factor Receptor Fusion-Positive Intrahepatic Cholangiocarcinoma With Humoral Hypercalcemia of Malignancy
    Chauhan, Aditya
    Likasitwatanakul, Pornlada
    Ahmed, Ammar
    Sibley, Shalamar D.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (04)
  • [38] Identification of a new fibroblast growth factor receptor, FGFR5
    Sleeman, M
    Fraser, J
    McDonald, M
    Yuan, SN
    White, D
    Grandison, P
    Kumble, K
    Watson, JD
    Murison, JG
    GENE, 2001, 271 (02) : 171 - 182
  • [39] Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms
    Auguste, P
    Gürsel, DB
    Lemière, S
    Reimers, D
    Cuevas, P
    Carceller, F
    Di Santo, JP
    Bikfalvi, A
    CANCER RESEARCH, 2001, 61 (04) : 1717 - 1726
  • [40] Expression of fibroblast growth factor receptor 2 (FGFR2) in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma: clinicopathological study
    Sasaki, Motoko
    Sato, Yasunori
    Nakanuma, Yasuni
    VIRCHOWS ARCHIV, 2024, 484 (06) : 915 - 923
12345